Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's Disease

Sponsor
NewAmsterdam Pharma
Study ID
NCT07794670
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Preclinical Alzheimer's Disease

Eligibility Criteria

Sex
ALL
Age
55 Years - 85 Years
Healthy Volunteers
Not accepted

Interventions

  • Obicetrapib 10 mg — DRUG
    once daily 10 mg Obicetrapib tablet
  • Matching placebo tablets — DRUG
    matching placebo tablet

Study Details

A study evaluating Obicetrapib in adults potentially at risk for Preclinical Alzheimer's Disease

Key Dates

First listed
Aug 31, 2026
Start date
Sep 30, 2026
Status verified
Aug 2026
Primary completion
Sep 30, 2028
Completion
May 31, 2029

Study Design

Enrollment
400 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION

Arms

  • Placebo Comparator: Placebo
    Placebo
  • Experimental: Obicetrapib
    10 mg Obicetrapib, once daily

Primary Outcome Measure

Change from Baseline to Week 52 in ptau 217 [ Time Frame: Baseline, Week 52 ]

Related Studies